Name: Oral Cancer: From Pathophysiology to Novel Therapeutic Approaches (en Inglés)
Price: 71780.00 CLP
Availability: InStock
Author: Vincent-Chong, Vui King
ISBN: 9783036597904

portada Oral Cancer: From Pathophysiology to Novel Therapeutic Approaches (en Inglés)

Formato

Libro Físico

Editorial

Mdpi AG

Autor

Vincent-Chong, Vui King

Idioma

Inglés

N° páginas

198

Encuadernación

Tapa Dura

Dimensiones

24.4 x 17.0 x 1.8 cm

Peso

0.63 kg.

ISBN13

9783036597904

Categorías

Biología

Oral Cancer: From Pathophysiology to Novel Therapeutic Approaches (en Inglés)

Vincent-Chong, Vui King (Autor) · Mdpi AG · Tapa Dura

Libro Nuevo

$ 71.780

$ 130.500

Ahorras: $ 58.720

45% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Jueves 25 de Julio y el Martes 06 de Agosto.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Oral Cancer: From Pathophysiology to Novel Therapeutic Approaches (en Inglés)"

Oral cancer is a commonly occurring head and neck cancer, with 90% of cases diagnosed as oral squamous cell carcinoma (OSCC). Histologically, OSCC is derived from a multistep mechanism known as oral carcinogenesis, which progresses from normal epithelium to hyperplasia, followed by dysplasia and carcinoma in situ, and precedes the development of invasive squamous cell carcinoma. This multistep mechanism is characterized by mutations related to copy number alteration and epigenetic modifications. Precision medicine based on genomic profiling is also becoming more prevalent. It relies on the genetic information of individual patients or specific cancer cells and how their genes interact with each other and the environment. This method can potentially provide more effective treatment strategies as approaches can be customized for the specific genetic profiles of patients. Completing the TCGA HNSCC database has led to the development of new therapeutic approaches and targeted therapies. Lately, immune checkpoint inhibitors have been recognized as one of the standards of care in HNSCC. However, although treating invasive SCC is crucial, implementing prevention strategies to preclude malignant transformation has been useful in clinical management. Topics of interest for this Special Issue include, but are not limited to: Precision medicine, i.e., targeted therapies that inhibit oral carcinogenesis and tumorigenesis mechanisms; Combination of novel therapeutic approaches with standard-of-care regimens in OSCC; Biomarkers, i.e., predictive and prognostic markers for therapeutic approaches.